Drug Profile
IONIS FXIRx
Alternative Names: BAY-2306001; FXI ASO; ISIS 404071; ISIS-416858; ISIS-FXIRXLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Bayer; Ionis Pharmaceuticals
- Class Anticoagulants; Antisense oligonucleotides; Antithrombotics
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Venous thromboembolism
- Discontinued Thrombosis
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-I for Thrombosis (Prevention, In volunteers) in USA (SC)
- 07 Sep 2021 Discontinued - Phase-II for Thrombosis (In the elderly, In adults) in Spain, Austria (SC)
- 07 Sep 2021 Discontinued - Phase-II for Thrombosis (Prevention) in Canada (SC)